NCT00000968View on ClinicalTrials.gov

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

Not specified

Study Completion Date

August 31, 1993

Conditions
HIV Infections
Interventions
BIOLOGICAL

gp160 Vaccine (Immuno-AG)

Trial Locations (1)

63104

St. Louis Univ. School of Medicine AVEG, St Louis

Sponsors

Collaborators (1)

Immuno-US
All Listed Sponsors
collaborator

Immuno-US

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH